<DOC>
	<DOCNO>NCT02385071</DOCNO>
	<brief_summary>The purpose study assess relative bioavailability ( extent drug substance become available body ) simeprevir ( SMV ) follow single dose administration age-appropriate oral formulation candidate compare 150 milligram ( mg ) capsule , assess effect food bioavailability SMV follow single dose administration select age-appropriate oral formulation candidate .</brief_summary>
	<brief_title>A Crossover Study Evaluate Relative Bioavailability Simeprevir Age-appropriate Oral Formulation Candidates Compared With 150-milligram ( mg ) Oral Capsule Healthy Adult Participants</brief_title>
	<detailed_description>This Phase 1 , open-label ( people know identity intervention ) , randomize ( study medication assign participant chance ) , 2-panel , 3-way crossover ( participant receive different intervention sequentially trial ) study healthy adult participant . Participants equally divide 2 panel , randomize panel . Participants allow switch panel . The study consist 3 part : Screening Phase ( , 28 day study commences Day 1 ) ; Open-label Treatment ( subsequent 3-treatment period Panel , separate washout period 7 day ) ; Post-Treatment Phase ( 7 day last study drug intake ) . The duration study per participant least 19 day , screen follow-up include . All eligible participant randomly assign 1 6 treatment sequence Panel . In fasted condition , study drug administer follow 10-hour overnight fast . In fed condition , participant also fast food 10 hour , consume high fat/high calorie breakfast within 30-minute period . Study drug administer 30 minute start breakfast . Participants allow food least 4 hour study drug administration . Blood sample collect evaluation pharmacokinetics pre-dose post-dose study treatment . Relative bioavailability SMV formulation evaluate primarily . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Participants must healthy basis physical examination , medical history , 12lead electrocardiogram ( ECG ) vital sign perform screen ( sign ICF ) , Day 1 first treatment session , applicable . If abnormality , participant may include Investigator judge abnormality deviation normal clinically significant . This determination must record participant 's source document Participants must willing able adhere prohibition restriction specify protocol study procedure Female participant , except postmenopausal woman , negative serum pregnancy test screen All female participant negative urine pregnancy test Day 1 first treatment session Male participant heterosexually active woman childbearing potential must agree use two effective method birth control men must donate sperm study least 30 day receive last dose study drug Female participant pregnant breast feed screen Day 1 first treatment session Participants current hepatitis A infection ( confirm hepatitis A antibody immunoglobulin [ IgM ] ) , hepatitis B infection ( confirm hepatitis B surface antigen [ HBsAg ] ) , hepatitis C infection ( confirm HCV antibody ) , human immunodeficiency virus type 1 ( HIV1 ) HIV2 infection Participants history evidence current past abuse alcohol , recreational narcotic drug , Investigator 's opinion would compromise participant 's safety and/or compliance study procedures Participants history clinically relevant skin disease , limited , dermatitis , eczema , drug rash , psoriasis , food allergy , urticaria Participants know allergy , hypersensitivity , intolerance simeprevir ( SMV ) excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Simeprevir</keyword>
	<keyword>Bioavailability</keyword>
</DOC>